CompletedPhase 3NCT03904693
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actelion
- Principal Investigator
- Hany Rofael, MDJanssen, LP
- Intervention
- FDC macitentan/tadalafil(drug)
- Enrollment
- 187 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Study locations (30)
- Providence Medical Foundation, Fullerton, California, United States
- University of Southern California, Los Angeles, California, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- WellStar Health System, Marietta, Georgia, United States
- OSF HealthCare Cardiovascular Institute, Peoria, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Norton Healthcare, Louisville, Kentucky, United States
- Sparrow Clinical Research Institute, Lansing, Michigan, United States
- Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States
- Washington University School Of Medicine, St Louis, Missouri, United States
- VA Sierra Nevada Health Care System, Reno, Nevada, United States
- The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Pitt County Memorial Hospital d/b/a Vidant Medical Center, Greenville, North Carolina, United States
- Sanford Health, Fargo, North Dakota, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03904693 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGNANCT07366879Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial HypertensionGolden Jubilee National Hospital
- RECRUITINGPHASE3NCT07245680COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →